Eloxx Pharmaceuticals, Inc. (ELOX) Stock Price & Analysis
Eloxx Pharmaceuticals, Inc. (ELOX) rose 10.10% to USD 11.01 as of June 10, 2026 at 03:03 UTC, according to Nexqual real-time market data.
ELOX last closed at USD 10; the session ranged USD 8.25–11.6 on volume of 281,585 shares. Market capitalization is $7.58M, with a 52-week range of USD 0–11.6 (PNK). Source: Nexqual, June 10, 2026 at 03:03 UTC.
Key Statistics (as of June 10, 2026 at 03:03 UTC)
| Price | USD 11.01 |
|---|---|
| Change | ▲ 10.10% (up) |
| Previous Close | USD 10 |
| Open | USD 10 |
| Day Range | USD 8.25 – 11.6 |
| 52-Week Range | USD 0 – 11.6 |
| Volume | 281,585 shares |
| Market Cap | $7.58M |
| Exchange | PNK |
Technical Analysis (ELOX)
Nexqual's technical model rates ELOX "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 03:03 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 67.18 (neutral) |
| vs SMA50 | Above (USD 2.44) |
| MACD | 1.76 (positive) |
Analyst Ratings (ELOX)
Wall Street analysts rate ELOX "None", per Nexqual as of June 10, 2026 at 03:03 UTC.
| Consensus Rating | None |
|---|
Earnings (ELOX)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -14.41 vs est -21.67 ▲ beat |
| 2023-06-30 | USD -21.56 vs est -16.94 ▼ miss |
| 2023-03-31 | USD -31.68 vs est -28.05 ▼ miss |
| 2022-12-31 | USD -33.55 vs est -32.67 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:03 UTC.
Financials & Fundamentals (ELOX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.53 |
| Total Cash | $6.36M |
| Total Debt | $11.82M |
Source: Nexqual, June 10, 2026 at 03:03 UTC.
Financial Health Score (ELOX)
Nexqual rates Eloxx Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:03 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $6M cash vs $12M debt |
| Cash Flow | Weak — Operating cash flow -$13M |
| Efficiency | Mixed — No data |
Ownership (ELOX)
| Shares Outstanding | 3.92M |
|---|---|
| Float | 532,179 |
| Short % of Float | +1.33% |
Source: Nexqual, June 10, 2026 at 03:03 UTC.
Leadership (ELOX)
Eloxx Pharmaceuticals, Inc. is led by Sumit Aggarwal (age 52), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:03 UTC.
| President, CEO & Director | Sumit Aggarwal (age 52) |
|---|---|
| Interim Chief Financial Officer | Daniel E. Geffken (age 68) |
From Eloxx Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Even if we succeed in bringing one or more products to the market, these products may not be considered cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EVLO | Evelo Biosciences, Inc. | USD 0 | ▲ 0% |
| CYCN | Cyclerion Therapeutics, Inc. | USD 3 | ▲ 0.67% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.36 | ▲ 2.27% |
| ARDS | Aridis Pharmaceuticals Inc. | USD 0 | ▲ 0% |
| SYBX | Synlogic, Inc. | USD 0.64 | ▼ 7.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:03 UTC. This page is informational and not investment advice.